菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

The Bispecifics Market Watch (Q1 2026 issue) delivers the latest updates in the bsAb industry, including clinical trials, strategic partnerships, regulatory milestones, emerging players, and innovation highlights, curated for scientists and decision-makers who need timely, actionable insights without the noise.

 

Q1 2026 Top Highlights:

 

      • FDA accepted Summit’s BLA for ivonescimab + chemo for EGFR-mutated NSCLC after TKI treatment.
      • UCB and Antengene signed a global ATG-201 (CD19/CD3) licensing deal worth ~$1.18B
      • Angitia raised $130M (Series D) to advance bone-building bispecifics for musculoskeletal diseases.
      • Janssen advanced a multiple myeloma trial with JNJ-79635322 (BCMA/GPRC5D/CD3).

Enter your details to download the newsletter